Advanced Antibody Formulations for Enhanced Stability and Shelf-Life

The present inventive concept relates to novel antibody compositions with adjustable pH ranges, optimized storage conditions, and advanced excipient combinations to ensure maximum stability and shelf-life, thereby revolutionizing the pharmaceutical industry.

The original patent disclosed a pharmaceutical composition comprising an antibody, glycine, acetate buffer, and polysorbate 80. However, the composition's stability and shelf-life were limited by the fixed pH range and storage conditions. The new inventive concept addresses these limitations by introducing adjustable pH ranges, optimized storage conditions, and advanced excipient combinations, enabling the development of more robust and reliable pharmaceutical products.

The novel antibody composition comprises an antibody or antigen-binding fragment thereof, glycine, acetate buffer, and polysorbate 80, with an adjustable pH range from 4.0 to 6.0. The antibody is modified to have enhanced stability at varying temperatures and storage conditions. The composition can be optimized for specific antibodies or antigen-binding fragments, ensuring maximum stability and shelf-life. Additionally, the inventive concept encompasses a method for optimizing storage conditions, a pharmaceutical composition with novel excipients, a system for real-time monitoring of composition stability, and a method for predicting and preventing protein degradation.

The new claims introduce a paradigm shift in pharmaceutical composition development by providing adjustable pH ranges, optimized storage conditions, and advanced excipient combinations. These innovations enable the creation of more stable and reliable pharmaceutical products, overcoming the limitations of the original patent.

Alternative embodiments of the inventive concept could include the use of different antibodies or antigen-binding fragments, varying excipient combinations, and adjustable pH ranges tailored to specific disease indications. Variations could also include the integration of machine learning algorithms and molecular modeling to predict and prevent protein degradation.

The inventive concept has significant commercial potential in the pharmaceutical industry, particularly in the development of novel treatments for autoimmune diseases, cancer, and inflammatory disorders. The target market includes pharmaceutical companies, biotechnology firms, and research institutions seeking to develop more robust and reliable pharmaceutical products.